LONDON, UK: RTW BIO, a biopharmaceutical and medical technology investment company, has completed its investment in Arix Bioscience, a life sciences venture capital firm, ahead of their planned merger. RTW BIO has acquired a 25.5% stake in Arix from Acacia Research Corporation for US$57 million, or £1.37 per share, and has committed to vote in…
All posts tagged Arix Bioscience
Depixus raises €30.6 million in Series A Financing
LONDON, UK: Arix Bioscience’s portfolio company Depixus has successfully completed its oversubscribed Series A financing which raised €30.6 million (£26.1 million). Depixus is a biotechnology company developing a unique technology for the fast, accurate, and straightforward extraction of multiomic information from DNA, RNA, and proteins. Funds from the financing will enable Depixus to further develop…
Arix Bioscience founds new portfolio company, Twelve Bio
LONDON: Arix Bioscience Plc, a global venture capital company focused on investing in and building breakthrough biotech companies, announced the foundation of a new portfolio company, Twelve Bio, which is developing novel engineered Cas12a nucleases for therapeutic gene editing. Arix is the sole investor in the company, with a 49% ownership stake. Twelve Bio is…